KOPPERS REPORTS THIRD QUARTER 2026 RESULTS

Koppers’ Q3 2026 sales rose 2.8% year over year to $499.1 million, but net income fell 38.2% to $14.7 million and adjusted EBITDA declined 18.2% to $58.0 million, as higher raw-material and logistics costs pressured margins. The company cut its 2026 adjusted EBITDA forecast to $220–$225 million from $240–$250 million and adjusted EPS guidance to $3.10–$3.25 from $3.80–$4.20, while maintaining operating cash flow guidance of $165–$185 million and raising free cash flow guidance to $115–$135 million. Year-to-date operating cash flow reached a record $126.9 million and free cash flow $92.0 million; Koppers also returned $56.2 million to shareholders and reduced net debt by $35.8 million.

Analysis

The key risk is not modest top-line growth but conversion: higher input and logistics costs are overwhelming volume and cost actions, while the earnings downgrade implies the recovery case is now increasingly dependent on 2027 pricing and restructuring delivery. Performance Chemicals is the only segment showing improving economics; continued share gains and utilization there partly cushion, but do not offset, deterioration in Railroad and Utility Products and especially Carbon Materials and Chemicals. The latter’s feedstock-quality and lower-utilization problems make its recovery less assured than a simple commodity-cost rebound would suggest.

Treat the stronger cash-flow narrative cautiously. Working-capital timing and inventory reduction support near-term liquidity, but are not a substitute for recovering EBITDA. At roughly $845 million of net debt against the new $220–225 million EBITDA outlook, net debt is about 3.8x that guide range; sustained margin weakness would limit flexibility, particularly if cash releases reverse. Buybacks alongside debt reduction therefore merit scrutiny rather than being read as proof of balance-sheet comfort.

Near term, guidance credibility and management’s conference-call detail on pass-through timing are the catalysts. Over 1–3 months, monitor raw-material/logistics costs, crosstie pricing, and whether CMC utilization stabilizes. Over 6–18 months, commercial price resets and plant actions could restore earnings, but benefits are not yet verified. The contrarian risk to a bearish read is that the downgrade may pull forward much of the bad news while self-help and pricing lagged costs; without valuation and post-release price data, conviction on outright downside is limited.

Key Decisions for Investors

• Keep KOP underweight; avoid adding on the cash-flow headline until call commentary confirms how much of the operating-cash-flow strength is repeatable versus working-capital timing.
• For an event-driven position, consider a defined-risk bearish KOP position only if the post-release price fails to stabilize and management cannot specify credible pass-through timing. Do not infer that the downgrade is underpriced without checking the market reaction and valuation.
• Reassess the downside thesis if quarterly adjusted EBITDA stabilizes, RUPS pricing stops eroding, and CMC utilization recovers; those are more meaningful confirmation points than reported sales growth.
• Track 2027 price realization, raw-material and logistics costs, CMC feedstock quality, working-capital reversal, and net debt. Failure to deliver margin recovery while net debt remains near current levels would undermine the self-help case; verified price resets and sustained cash conversion would falsify the bearish view.